Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight is poised for success as they continue to implement their commercial strategy and see improvements in their utilization rates and quarterly placements. The company's revenue beat consensus and management is confident in their guidance for achieving $120-135M in revenue in 2026. With the potential for faster LDD installed base growth, higher utilization, and margin improvement, there is potential for upside. Though there are risks, such as limited adoption and competition in the IOL market, the undemanding valuation and achievable guidance make RxSight a solid buy.

Bears say

RxSight is facing significant challenges and risks that may hinder its ability to achieve future growth and profitability. These include limited adoption of its light-adjustable lenses due to the need for an additional piece of capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and potential for dilutive financing rounds. The company's most recent financial guidance for 2026 was below market expectations for revenue and gross margin, and the company also expects to continue investing in operating expenses, potentially impacting profitability.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.